Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
about
Progress in treatment of ANCA-associated vasculitisGranulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestationsSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Updates in ANCA-associated vasculitisThe effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitisEfficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case seriesImpact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.Cardiac Involvement in Granulomatosis with PolyangiitisLow immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature.Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA).ANCA-Associated Systemic Vasculitis Presenting With Hypertrophic Spinal Pachymeningitis: A Report of 2 Cases and Review of Literature.Rituximab in immunologic glomerular diseases.Advances in therapy for ANCA-associated vasculitis.Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?New-generation therapy for ANCA-associated vasculitis.Granuloma in ANCA-associated vasculitides: another reason to distinguish between syndromes?Impact of rituximab trials on the treatment of ANCA-associated vasculitis.Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab.Treatment of ANCA-associated vasculitis.Cranial neuropathies in granulomatosis with polyangiitis (Wegener's): a case-based review.Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?Treatment of severe and/or refractory ANCA-associated vasculitis.B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?Vasculitis for the internist: focus on ANCA-associated vasculitis.Emerging trends in the formation and function of tuberculosis granulomas.The efficacy of submucosal corticosteroid injection and dilatation in subglottic stenosis of different aetiology.[Treatment strategies for ANCA-associated vasculitides].Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis.Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.[Established medications : new areas of application].Retro-orbital granuloma associated with granulomatosis with polyangiitis: a series of nine cases.
P2860
Q21195258-959C949E-165A-47B6-9C08-553EF7149428Q26748200-4AB27F53-F404-4C8A-AFF3-6D4C4BEAABE2Q26776308-596388D3-03BE-41FD-BED3-5DE88D4C40C4Q27025692-EA428227-B241-4AFD-8F1A-6EB21CF3ED8DQ28069897-FC68E445-CC35-442C-A42B-CC4E7BEEB306Q33683956-DE1E7ED3-1FA6-4BF1-BD1E-871C5F90E5A4Q33706447-6D668045-E044-423B-AEDA-AE056A10BA4EQ33706866-C39743DB-0431-4EE3-B9C7-FE62024BD5F2Q33757209-19C55788-4DFB-49D8-85C1-44BE86D74F8DQ34282077-E0104C2C-CA9E-4427-9920-97468EBB273FQ34377832-6A7E7D03-C613-4C1D-A444-1CE5E2FF1B99Q34960458-0FB26B21-74EF-48D3-8540-B691A847ECACQ35861654-F33F1ED5-7C86-4324-A319-65472CA5D5BFQ35887318-C4AD95B9-ED1E-4653-8E33-BAB750945511Q36152127-5C0FDCD6-3BD8-4684-9F10-221716CC4D1CQ36152477-6F5D5ED6-8746-4E2C-9691-DA7BF993467DQ36299301-00B144C2-06D0-4BA0-9D16-EAC9483C9C85Q37989298-61565779-4456-484D-853D-4DE57ADE507EQ38034940-CF792697-669A-43AF-A330-C3569B425962Q38100780-7D0B21F1-0A6C-43DA-88BF-3C3ACAE26199Q38113507-8622EAE5-5B76-4308-824B-692E06E99319Q38135271-7EA23B68-C740-4ED0-BE88-438814B79783Q38146909-6AF75CF4-7AD8-4002-ACD7-29CBCA5F62F8Q38152651-1B5CA0A6-BE81-4D85-B73B-3E106AEB60E6Q38155087-332B86DF-8707-4613-911C-3571CE911E3FQ38159916-FDF5BA88-450B-46FE-9BCD-3EB377818156Q38172430-5D0AC6EA-3A11-4B89-9651-E1A77F526942Q38204971-135ADFA2-B548-44C6-A85F-09FF9D00EAD8Q38219932-9E076451-36AE-4A9A-A299-621D9E172DDEQ38371009-05AB79DF-DE46-459A-BBA1-DDF6DA13B031Q38543360-9F6E68FC-420B-44CA-914B-51C23AD34FAFQ39379384-FBFF94B5-9360-40B5-ABAD-84219DC6F6FDQ39487696-AFAB2175-68FB-4F4C-B616-FD5433989AADQ39819424-EA43B11C-CC5D-4F14-A168-6C9EFD721C17Q41192540-AF3DD50A-3962-4E1F-8D24-9A9866E19BF6Q41605329-4424E06A-DB58-4F81-A5BD-6FC1296CA275Q42239031-21008A80-BD49-4E61-9B24-A21F6AF36406Q43416268-5671212A-FC0B-4CEB-BEA1-125BFBD0044FQ44480906-7D940A0B-C1C3-4BAC-A6D1-8BF73A81DE8CQ44641551-0E455DED-8309-4390-AECC-995193FD9DE0
P2860
Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Rituximab for refractory granu ...... sus vasculitic manifestations.
@en
Rituximab for refractory granulomatosis with polyangiitis
@nl
type
label
Rituximab for refractory granu ...... sus vasculitic manifestations.
@en
Rituximab for refractory granulomatosis with polyangiitis
@nl
prefLabel
Rituximab for refractory granu ...... sus vasculitic manifestations.
@en
Rituximab for refractory granulomatosis with polyangiitis
@nl
P2093
P356
P1476
Rituximab for refractory granu ...... sus vasculitic manifestations.
@en
P2093
Bernhard Noelle
Christin Dubrau
Eva Reinhold-Keller
Julia U Holle
Karen Herlyn
Martin Heller
Petra Ambrosch
Wolfgang L Gross
P304
P356
10.1136/ARD.2011.153601
P407
P577
2011-10-21T00:00:00Z